Company intelligence / Profile preview

Quintrigen

Rehovot or vicinity, Central District, Israelquintrigen.co.il ↗

Ownership: Private
Development stage: Preclinical

Overview

Quintrigen is developing a novel family of small peptides capable of refolding and reactivating mutant p53 proteins, aiming to restore their tumor-suppressing function. This approach targets a major unmet need in oncology since mutated p53 drives about half of all human cancers. The technology has shown promise in preclinical research; clinical results are not yet available[1][3].

Therapeutic areas: Oncology
Modalities: PeptidesSmall peptides (specifically targeting protein refolding)
Industry: Biotech

Partnerships

BL Corporation/BioLeaders Co., Ltd. (Korea)Weizmann Institute of Science[1][7]

Beyond the preview

Go deeper on Quintrigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quintrigen.

Explore the full profile